$84.72
-0.03 (-0.04%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CRNX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
19 interventional · 5 with posted results
Held by 7 tracked-famous managers (MARSHALL WACE, LLP, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, Man Group plc, Point72 Asset Management, L.P., +2 more) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: 1 congress / 0 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)NCT07159841Change from baseline in morning serum androstenedione (A4) (Part A)Randomized · Triple-masked · Treatment | Phase 2/3 | Recruiting | Drug: Atumelnant, Placebo | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | 153 | Mar 2030 | ≤ 1,320 d | 2026-08-12 |
| An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal HyperplasiaNCT06712823Incidence of treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), adverse events of special interest (AESI [adrenal insufficiency]) and any adverse events (AEs) leading to discontinuationOpen-label · Treatment | Phase 2 | Recruiting | Drug: atumelnant (CRN04894) | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | 200 | Jul 2029 | ≤ 1,077 d | 2026-06-29 |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenNCT07087054Participants will record the number of flushing per day in a daily diary to assess the efficacy of paltusotine vs placebo in reducing flushing episodes.Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Paltusotine, Placebo | Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor | 141 | Aug 2027 | ≤ 377 d | 2026-08-04 |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid TumorsNCT07129252(Dose Escalation) Incidence and severity of DLTs.Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: CRN09682 | SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm | 150 | Aug 2027 | ≤ 377 d | 2026-07-31 |
| A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaNCT07144163Proportion of participants with morning post-GC A4 ≤ ULN who are on physiologic GC replacement.Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Atumelnant, Placebo | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | 150 | May 2027 | ≤ 285 d | 2026-08-12 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeNCT05804669Proportion of participants with treatment emergent adverse events (TEAEs)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: atumelnant | Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome | 19 | Oct 2026 | ≤ 73 d | 2026-08-19 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)NCT04261712Incidence of treatment-emergent adverse events (TEAEs) throughout the studyOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine). | Drug: Paltusotine | Acromegaly | 43 | 2026-06-30actual | — | 2026-07-29 |
| Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsNCT07570082Cohort 1: Pharmacokinetics (AUC 0-last)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Atumelnant, Carbamazepine, Midazolam, Digoxin, Metformin | Healthy Volunteers | 46 | 2026-06-30actual | — | 2026-08-19 |
| A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian ParticipantsNCT07221084Pharmacokinetics (Cmax)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Atumelnant, Placebo | Healthy Volunteers | 21 | 2026-02-07actual | — | 2026-03-11 |
| Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)NCT05907291Change from baseline in morning (before 11:00) serum androstenedione (A4)Open-label · Treatment | Phase 2 | Completed | Drug: atumelnant (CRN04894) | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | 38 | 2025-08-22actual | — | 2025-09-23 |
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid SyndromeNCT05361668results2025-10-31Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine | Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas | 36 | 2024-03-07actual | — | 2026-03-19 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)NCT05192382results2026-01-13Percentage of Participants With a Biochemical Response in Insulin-like Growth Factor-1 (IGF-1) at the End of the Randomized Control Phase (EOR)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine). | Drug: Paltusotine, Placebo | Acromegaly | 111 | 2024-01-20actual | — | 2026-07-15 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of AcromegalyNCT04837040results2026-01-13Percentage of Participants Who Maintain Biochemical Response in IGF-1 (≤1.0× the Upper Limit of Normal [ULN]) at the End of the Randomized Control Phase (EOR)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine). | Drug: Paltusotine, Placebo | Acromegaly | 58 | 2023-07-10actual | — | 2026-07-15 |
| Single and Multiple-Ascending Dose Study of CRN04894 in Healthy VolunteersNCT06048887Percentage of subjects with treatment-emergent adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: CRN04894 Oral Solution, Placebo Oral Solution | Healthy Volunteers | 88 | 2022-04-11actual | — | 2023-09-21 |
| An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)NCT03789656results2025-02-17Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) LevelOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Paltusotine | Acromegaly | 47 | 2020-08-03actual | — | 2025-02-17 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)NCT03792555results2025-03-17Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Paltusotine, Placebo | Acromegaly | 13 | 2020-07-15actual | — | 2025-03-17 |
| A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult VolunteersNCT03936166Number of participants with treatment emergent adverse events by severityRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: CRN01941 Oral Solution, CRN01941 Oral Capsule, Placebo Oral Solution, Placebo Oral Capsule | Healthy Volunteers | 57 | 2019-12-16actual | — | 2020-11-04 |
| Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy VolunteersNCT04246749Mass balance of CRN00808Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: [14C]-CRN00808, CRN00808 | Healthy Volunteers | 11 | 2019-10-25actual | — | 2020-01-29 |
| Single and Multiple-Ascending Dose Study of CRN00808 in Healthy VolunteersNCT03276858Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of CRN00808 single ascending doses using clinical assessments, telemetry, and Holter monitoring and subject self-reportingRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: CRN00808, Placebo Oral Solution, Midazolam oral solution, Placebo oral capsule | Healthy Volunteers | 99 | 2018-04-30actual | — | 2018-08-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19